Despite many cases being preventable, melanoma remains one of the most common cancers. Patients with resected stage II or III lesions often develop distant metastases – but current methods cannot accurately predict who is most at risk. Rebecca Lee, a research associate at the University of Manchester, is first author on research that investigates the predictive potential of circulating tumor DNA (1). We spoke with her to find out how genetic testing using ctDNA could improve patient care.
Newsletters
Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.
References
- RJ Lee et al., “Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma”, Ann Oncol, [Epub ahead of print] (2018). PMID: 29112704.